|
|
News Breaks | | | | September 25, 2012 | | 09:03 EDT |  | SGEN | Seattle Genetics completes patients enrollment for clinical trial of ADCETRIS
Seattle Genetics and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company, announced the completion of patient enrollment in a phase III clinical trial of ADCETRIS, or brentuximab vedotin, for post-transplant Hodgkin lymphoma, or HL, patients. The phase III trial, also known as the AETHERA trial, is evaluating ADCETRIS versus placebo for the treatment of patients at high risk of residual Hodgkin lymphoma following autologous stem cell transplant. ADCETRIS is an antibody-drug conjugate directed to CD30, a defining marker of classical HL. | |
|
News For SGEN From The Last 14 Days Check below for free stories on SGEN the last two weeks. |
|
|
| May 14, 2013 | | 09:04 EDT | | SGEN | Seattle Genetics announces ADCETRIS supplemental filing accepted by FDA
 Subscribe for More Information | |
|
|
|
|
|
|
